CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Gesloten

SectorIndustrieƫn

210.17 0.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

209.19

Max

210.4

Belangrijke statistieken

By Trading Economics

Inkomsten

2B

Verkoop

-5.7B

2.5B

K/W

Sectorgemiddelde

21.941

38.367

EPS

2.04

Dividendrendement

1.39

Winstmarge

24.437

Werknemers

29,904

EBITDA

-2.4B

858M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.44% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.39%

2.26%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-24B

100B

Vorige openingsprijs

210.02

Vorige sluitingsprijs

210.17

Nieuwssentiment

By Acuity

38%

62%

142 / 459 Rangschikking in Industrials

CSL Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 aug 2025, 03:32 UTC

Belangrijke Marktbewegers

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 aug 2025, 23:46 UTC

Winsten

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 aug 2025, 22:15 UTC

Winsten

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 feb 2025, 21:55 UTC

Winsten

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Winsten

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18 aug 2025, 23:46 UTC

Marktinformatie
Winsten

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 aug 2025, 21:52 UTC

Winsten

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 aug 2025, 21:51 UTC

Winsten

CSL to Cut Up to 15% of Staff>CSL.AU

18 aug 2025, 21:49 UTC

Winsten

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 aug 2025, 21:49 UTC

Winsten

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 aug 2025, 21:48 UTC

Winsten

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 aug 2025, 21:47 UTC

Winsten

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 aug 2025, 21:46 UTC

Winsten

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 aug 2025, 21:45 UTC

Winsten

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 aug 2025, 21:45 UTC

Winsten

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 aug 2025, 21:44 UTC

Winsten

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 aug 2025, 21:43 UTC

Winsten

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 aug 2025, 21:43 UTC

Winsten

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 aug 2025, 21:42 UTC

Winsten

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 aug 2025, 21:42 UTC

Winsten

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 jun 2025, 02:15 UTC

Marktinformatie

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 apr 2025, 07:01 UTC

Marktinformatie

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mrt 2025, 02:03 UTC

Marktinformatie

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Marktinformatie

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Winsten

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Winsten

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Winsten

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Winsten

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Winsten

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Peer Vergelijking

Prijswijziging

CSL Ltd Prognose

Koersdoel

By TipRanks

35.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 283.415Ā AUDĀ  35.44%

Hoogste 330Ā AUD

Laagste 227.5Ā AUD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor CSL Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Sentiment

By Acuity

142 / 459 Rangschikking in Industrieƫn

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat